Category Archives: SM04554

Samumed’s Compound Structure

I have covered Samumed and its SM04554 compound to treat hair loss dozens of times in the past. Phase 3 Trials ending in 2020. Please use the categories menu of this blog to find my past posts on this company.

Samumed is aiming to treat numerous medical and cosmetic conditions via activating and/or modulating the Wnt signaling pathway. Of all those targeted conditions, androgenic alopecia is the furthest ahead and the only one that is currently in Phase 3 Trials:

Samumed Pipeline 2019
Samumed Pipeline: https://www.samumed.com/pipeline/default.aspx

Samumed Compound Structure

A few days ago, a reader named “Thomas” emailed me about a new Samumed patent (Publication date = November 22, 2018; Filing date = December 27, 2017).

Thomas pointed out something very interesting. For the first time ever, Samumed has published the chemical structure of its main Wnt/ß-catenin signaling compound. Right under the section titled “Abstract” in the above linked new patent.

Samumed Compound Molecule
Samumed’s Compound Chemical Structure.

Samumed has a decade-long online trail of numerous filed patents, with the vast majority of them including the names of their key scientists John Hood and Sunil Kumar. I have not tried to go through all of these online patent documents, especially those not focused on androgenetic alopecia (male pattern hair loss).

So I am not certain if the above chemical compound structure image is the first time that it has ever been released. It is also not clear if all of  Samumed’s products will be very close in structure to the above compound image. The company has published compound images in the past that look very different from the above (e.g., the one in here for cancer treatments; another in here for Indazole-3-carboxamides and their use as Wnt/β-catenin inhibitors and more).

It would be useful if readers (especially the Chemistry experts on here) provide relevant feedback to this post. For example:

  • What does this compound’s molecular structure mean and how is it unique from other compounds (Samumed ones and non-Samumed ones) that modulate Wnt/ß -catenin signaling?
  • How does this latest compound image differ from other related compound images that Samumed has published in the past?
  • If this really is the first time that this particular image has been released by Samumed, why so late in the process?

Samumed to Initiate Phase 3 Clinical Trials

When it comes to a hair loss cure or groundbreaking new hair loss treatment, Samumed is one of the favorites to come out with something significant in the next several years. I have covered Samumed and its SM04554 hair loss product numerous times on this blog in the past. The product works via the activation of the Wnt signaling pathway and subsequent epithelial β-catenin signaling.

The company’s CEO Dr. Osman Kibar has been widely covered in the media, including a cover appearance on Forbes magazine in 2016. They also got publicity in 2018 in Business Insider after announcing plans to go public in 3-4 years.

Earlier today, reader “chris2” pointed out that Samumed is starting its final Phase 3 clinical trial for its SM04554 product. This news is provided in Samumed’s latest monthly newsletter (subscribe here). The best part of this story is that these trials will entail 625 patients, which is incredible. I do not remember hair loss companies ever testing their product on so many people in clinical trials. More often than not, they test on less than 50 human volunteers.

It is not surprising that Samumed can go all out with these trials. They have been valued at a massive $12 billion, and earlier this month, they received $438 million in new equity funding.

So in just this summer of 2018, we have received highly favorable news from: Samumed, CassiopeaHistogen, RiverTown, Follicum, Organ Technologies/RIKEN/Tsuji. I hope Follica and Shiseido are next in line.